Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry Z Shen

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Therapeutic Innovation & Regulatory Science|September 22, 2018
A Novel Design for Decision Rules Based on Statistical Testing Strategies of Binary Endpoints in a Definitive Go/No-Go Single-Treatment Clinical StudyMing Zhou, Larry Z Shen
Journal of Biopharmaceutical Statistics|March 11, 2008
A Bayesian approach to utilizing prior data in new drug developmentLarry Z Shen, Todd Coffey, Wei Deng
Obesity (Silver Spring, Md.)|January 23, 2010
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trialLouis J Aronne, Amy E Halseth, Colleen M Burns, et al.
Diabetes/Metabolism Research and Reviews|September 3, 2004
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetesMark S Fineman, Larry Z Shen, Kristin Taylor, et al.
Diabetes Care|July 29, 2003
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetesMark S Fineman, Thomas A Bicsak, Larry Z Shen, et al.
Diabetes Care|March 1, 2003
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trialPriscilla A Hollander, Philip Levy, Mark S Fineman, et al.
Diabetes Care|March 11, 2010
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeksJohn B Buse, Daniel J Drucker, Kristin L Taylor, et al.
Clinical Pharmacokinetics|December 15, 2010
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosingMark Fineman, Shawn Flanagan, Kristin Taylor, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Therapeutic Innovation & Regulatory Science|September 22, 2018
A Novel Design for Decision Rules Based on Statistical Testing Strategies of Binary Endpoints in a Definitive Go/No-Go Single-Treatment Clinical StudyMing Zhou, Larry Z Shen
Journal of Biopharmaceutical Statistics|March 11, 2008
A Bayesian approach to utilizing prior data in new drug developmentLarry Z Shen, Todd Coffey, Wei Deng
Obesity (Silver Spring, Md.)|January 23, 2010
Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trialLouis J Aronne, Amy E Halseth, Colleen M Burns, et al.
Diabetes/Metabolism Research and Reviews|September 3, 2004
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetesMark S Fineman, Larry Z Shen, Kristin Taylor, et al.
Diabetes Care|July 29, 2003
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetesMark S Fineman, Thomas A Bicsak, Larry Z Shen, et al.
Diabetes Care|March 1, 2003
Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trialPriscilla A Hollander, Philip Levy, Mark S Fineman, et al.
Diabetes Care|March 11, 2010
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeksJohn B Buse, Daniel J Drucker, Kristin L Taylor, et al.
Clinical Pharmacokinetics|December 15, 2010
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosingMark Fineman, Shawn Flanagan, Kristin Taylor, et al.
Pageof 1